Risk factors
Rhythm Pharmaceuticals (RYTM) risk factors
Item 1A of every Rhythm Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors67 risks10 new11 dropped19 reworded
Rhythm Pharmaceuticals highlights risks around financing its pipeline, commercializing setmelanotide, and navigating international regulatory and pricing pressures.
Filed Feb 26, 2026 - FY2024 10-K risk factors68 risks
Rhythm Pharmaceuticals faces significant commercial, financial, and regulatory risks driven by its reliance on the success and market acceptance of IMCIVREE for rare genetic obesity. The company depends heavily on third-party manufacturers, licensed intellectual property from Ipsen and LGC, and the need for additional capital to fund clinical development.
Filed Feb 28, 2025